The Center for Breakthrough Medicines and Penn’s Gene Therapy Program (GTP), led by James Wilson, MD, PhD, Director of the GTP and Rose H. Weiss Professor of Medicine and Pediatrics, entered into a multi-year collaboration focusing on the manufacturing and testing of modern gene therapy processes and products.
The renewable research and development collaboration facilitated by PCI combines Penn’s expertise in gene therapy development with the King of Prussia-based center’s growing manufacturing capacity. The partnership will also ideally help other small biotech firms, universities, and large pharmaceutical companies in advancing gene therapies from discovery to human testing with the potential for less risk and expense.